Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Subspecialties Neurology, Oncology

The Shapeshifting Cancer

Credit: YA Yabo et al.

Glioblastoma is an aggressive cancer that can form in the brain or spinal cord, with an average survival outlook of 12 to 18 months – even with the wide range of treatments available. Where does the disconnect lie between relentless treatment and survival? It’s near impossible to prevent glioblastoma recurrence, meaning that patients face therapy-resistant relapses with a bleak outlook.

Researchers from the NORLUX Neuro-Oncology Laboratory at the Luxembourg Institute of Health (LIH) decided that we can do better. By reviewing recent literature on glioblastoma plasticity and its role in creating heterogeneous cells, they uncovered several reasons these cancers are so good at coming back (1). Some glioblastoma cells carry stem cell properties, allowing the establishment of heterogeneity that can be difficult to overcome. To make matters worse, glioblastoma cells can also change the way they look and function in response to their environment. This plasticity, combined with the recurring nature of the tumors, makes glioblastoma an even deadlier enemy.

Credit: YA Yabo et al.

“Cellular states interact dynamically with each other and with the surrounding brain to shape a flexible tumor ecosystem, which enables swift adaptation to external pressure, including treatment,” explained lead author Yahaya Yabo (2). Therefore, the aim of the literature review was to identify insights into potential new treatments that could target the cancer’s plasticity.

The review highlighted the need for a shift in how glioblastoma and other aggressive tumors are treated, but left the door open for exactly which therapies could be effective. “[Glioblastoma] eradication will require targeting the dynamic states rather than single entities,” said Simone Niclou, director of the Department of Cancer Research at LIH (2). “Further studies are needed to reveal the drivers of plasticity and treatment escape. These should address which of the changes are fast and reversible, and which are retained in tumors long after treatment.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. YA Yabo et al., Neuro Oncol, [Online ahead of print] (2021). PMID: 34932099.
  2. Luxembourg Institute of Health (2022). Available at: https://bit.ly/3Ie3E3r.
About the Author
Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register